One of the abiding philosophies of the Johns Hopkins Division of Rheumatology is that the critical pathway to understanding human autoimmune rheumatic diseases is through the study of large numbers of well-defined patients, followed over time, with the collection of rich phenotypic data, mapping disease trajectory, and where possible, acquiring and storing relevant biological materials from blood and target tissue. This repository of data and samples can then be used to separate heterogeneous diagnostic groups into more homogeneous subgroups, using tools that span the entire spectrum of investigation. This P30 will focus on providing the framework for organizational (oversight, management), operational (recruitment, sampling, processing), measurement and analytical (statistical, computational, and integrative) expertise to enable effective clinical and translational research. The Hopkins RDRCC competitive renewal comprises an Administrative Core (Core A) led by Drs. Rosen and Bingham, and includes 3 scientific Cores: (i) Core B is the Research Management and Patient Integrated Data (RAPID) Core, led by Dr. Bingham; (ii) Core C is the Sample Processing and Immunoassay Research (SPIRE) Core, led by Drs. Casciola-Rosen and Soloski; and Core D is the Data Science Core, led by Dr. Scott Zeger. The Center is structured as a matrix, designed to foster collaborative and synergistic discovery by maximizing access of the diverse research community to data and samples from humans with rheumatic diseases. Core A will promote efficient, interdisciplinary research throughout the research community and Cores, and manage the enrichment program. Core B will facilitate studies on humans with rheumatic diseases, by providing research management and oversight functions, enhancing research integration with the Epic EHR, and enable patient-centered outcome research. Core C will provide assistance with patient sample acquisition, processing, storage and distribution, as well as provision of multiple immunological assays for discovery and validation of biomarkers and disease pathways. Core D will provide highly innovative tools to enable analysis of complex longitudinal data in rheumatic disease patients, particularly with the design and application of Bayesian hierarchical models to identify disease subsets.

Public Health Relevance

This Rheumatic Diseases Resource-based Core Center provides systems and infrastructure to facilitate efficient and significant research on humans with autoimmune rheumatic diseases. The synergies that arise from coupling the diverse and well- resourced research community to the unusually rich collection of prospectively collected data and samples from patients with rheumatic diseases through provision of Core service and expertise provides unprecedented opportunities to enhance and accelerate discovery into the causes, mechanisms, diagnosis, therapy and prevention in these diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR070254-03
Application #
9533169
Study Section
Special Emphasis Panel (ZAR1)
Program Officer
Mancini, Marie
Project Start
2016-09-08
Project End
2021-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Wohlfahrt, Alyssa; Bingham 3rd, Clifton O; Marder, Wendy et al. (2018) Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS) Measures in RA Patients Starting or Switching a DMARD. Arthritis Care Res (Hoboken) :
Darrah, Erika; Giles, Jon T; Davis, Ryan L et al. (2018) Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis. Front Immunol 9:2696
Leung, Ying Ying; Ogdie, Alexis; Orbai, Ana-Maria et al. (2018) Classification and Outcome Measures for Psoriatic Arthritis. Front Med (Lausanne) 5:246
Bartlett, S J; Gutierrez, A K; Butanis, A et al. (2018) Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. Qual Life Res 27:2443-2451
Darrah, Erika; Yu, Fang; Cappelli, Laura C et al. (2018) Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis. Arthritis Rheumatol :
Albayda, Jemima; Bingham 3rd, Clifton O; Shah, Ami A et al. (2018) Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatology (Oxford) 57:760-762
Cappelli, Laura C; Konig, Maximilian F; Gelber, Allan C et al. (2018) Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. Arthritis Res Ther 20:59
Igusa, Takeru; Hummers, Laura K; Visvanathan, Kala et al. (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77:1179-1186
Cappelli, Laura C; Brahmer, Julie R; Forde, Patrick M et al. (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553-557
Lee, Yvonne C; Bingham 3rd, Clifton O; Edwards, Robert R et al. (2018) Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Arthritis Care Res (Hoboken) 70:197-204

Showing the most recent 10 out of 22 publications